Related Experiment Video

Updated: Aug 6, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

MET alterations in advanced non-small cell lung cancer

Mandy Sakamoto1, Tejas Patil1

  • 1Department of Medicine, Division of Medical Oncology, United States.

Lung Cancer (Amsterdam, Netherlands)
|March 16, 2023
PubMed

Insights

Targeting the MET pathway is crucial for advanced non-small cell lung cancer (NSCLC) due to its role in driving cancer growth and resistance. This review covers MET biology, diagnostics, and new therapies for NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The MET pathway is a key driver in non-small cell lung cancer (NSCLC).
  • MET activation contributes to both primary tumor growth and acquired resistance to therapies.
  • Diverse mechanisms of MET activation present diagnostic and therapeutic challenges.

Purpose of the Study:

  • To review the biology and mechanism of MET as a driver mutation in advanced NSCLC.
  • To discuss distinct MET alterations and their diagnostic challenges.
  • To explore the significance of MET in acquired resistance and novel treatment strategies.

Main Methods:

  • This is a narrative review.
  • Literature search on MET pathway, NSCLC, driver mutations, resistance, and targeted therapies.
  • Synthesis of current knowledge on MET biology and clinical implications.

Main Results:

  • MET pathway dysregulation is a clinically relevant mechanism in advanced NSCLC.
  • Various MET alterations necessitate specific diagnostic approaches.
  • MET plays a critical role in the development of acquired resistance.
  • Emerging MET-directed therapies show promising clinical outcomes.

Conclusions:

  • Understanding MET alterations is vital for effective NSCLC treatment.
  • MET-targeted therapies represent a promising therapeutic avenue for advanced NSCLC.
  • Continued research into MET biology and resistance mechanisms is essential.
Keywords:
MET alterationsMET amplificationMET exon 14 skippingMET overexpressionNSCLC

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K